

PRESS RELEASE

FOR IMMEDIATE RELEASE

9 AUGUST 2007

PHARMACY CHAIN 36.6 H1 2007 PRELIMINARY RESULTS

AUGUST 9, 2007, MOSCOW – OAO Pharmacy Chain 36.6 [RTS:APTK; MICEX:RU14APTK1007] announces preliminary results on sales volumes and business operations for the first half of 2007 according to management reports.

Sales

- The consolidated sales for H1 2007 according to management accounts totaled US\$385 million, which represents 77% y-o-y growth.*
- Sales in the pharmacy segment amounted to US\$300 million, an increase of 90% y-o-y. In Q2 2007 retail sales amounted to US\$151 million, up 78% over the same period in 2006.
- Veropharm [RTS:VRPH, MICEX:VRFM] sales grew 29% and reached US\$58.2 million.
- During H1 2007 sales of the European Medical Center (EMC) totaled US\$12.9 million.

<i>Thousand USD</i>	Consolidated	Retail	Veropharm	EMC
H1 2007*	385 000	300 000	58 200	12 900
H1 2006	217 600	157 800	45 200	-
<i>Change y-o-y</i>	76.9%	90.1%	28.8%	-

Number of stores

- At the end of H1 2007 Pharmacy Chain 36.6 had a total of 936 pharmacies situated in 26 regions throughout Russia. Pharmacies in the regions accounted for 54.3% of sales in the pharmaceutical retail segment.

- In Q2 2007 Pharmacy Chain 36.6 acquired the Zdravnik pharmacy chain, which included 48 pharmacies in the city of Yekaterinburg and surrounding Sverdlovsk region. In 2006 the Zdravnik chain reported US\$23.4 million in revenues.
- During Q2 2007, a total of 43 pharmacies were opened organically, 7 pharmacies were rebranded and 9 pharmacies were closed.
- In Q2 2007 the fifth Early Learning Center (ELC) store was opened in Moscow.

Operational results for retail business

- During the first half of 2007, 46.4 million purchases were made, which is 80% more than in the same period of 2006. The average receipt for pharmacies operating more than a year rose by 35% and reached US\$8.4; the average receipt for the Moscow business unit was up 34% to US\$11.6, while the average receipt in regional pharmacies rose 38% to US\$6.0.
- Average sales floor size at the end of H1 2007 was 62.7 square meters, down 15% y-o-y.
- Revenues per square meter of sales floor in pharmacies that had been operating for more than a year totaled US\$5400, up 33% y-o-y. Revenues per square meter in Moscow pharmacies were up 25% to US\$5900, while revenues per square meter in the regional pharmacies were up 44% to US\$5100.
- Sales growth (like-for-like, in US dollars) in the chain's pharmacies that had been opened or acquired prior to 1 January 2006 amounted to 34.6%. Sales growth at the matured pharmacies was primarily due to a higher average ticket size at the regional pharmacies.

Business Unit	Number of pharmacies	H1 2007	
		Share in sales	Average sales floor
Moscow	284	45.7%	82.4
Urals	330	25.4%	55.0
South	123	13.1%	47.1
Volga	124	10.0%	58.0
North-West	33	3.0%	68.8
Western Siberia	42	2.8%	45.5
<i>Company total:</i>	936		62.7

Pharmacy operational results according to opening/acquisition date:

	Number of pharmacies	Share in sales	Average ticket, USD
Opened/acquired before 1 January 2006	395	42.7%	8.4
Opened/acquired after 1 January 2006	541	57.3%	4.9
<i>Company total:</i>	936		6.4

Debt

- The net debt of Pharmacy Chain 36.6 at the end of H1 2007 stood at US\$263.6 million, including US\$21.4 million of Veropharm's debt.

** here and hereinafter financial indicators may significantly differ from the IFRS consolidated data.*

For further information please contact:

*Mikhail Kolosov,
Corporate Communications &
Investor Relations Manager*

*kolosov@oao366.ru
Tel.: (+7495) 792 52 07*

or refer to the Company's web-site

www.pharmacychain366.com

Notes to the Editor:

Pharmacy Chain 36.6 is the first public national health and beauty retailer listed in the "B"-list on RTS (ticker: APTK) and off-list on MICEX (ticker: RU14APTK1007). Market capitalisation as of 08.08.07 was USD 656 million based on RTS share prices.

Pharmacy Chain 36.6 operates over 1000 stores in 28 regions and 90 cities in Russia.

OAO Veropharm, the Company's generics subsidiary, is one of Russia's top five manufacturers (according to Pharmexpert research). Veropharm's shares are traded in the "B"-list on RTS (ticker: VRPH) and off-list on MICEX (ticker: VRFM). Market capitalisation as of 08.08.07 was USD 457 million based on RTS share prices.

ZAO Apteki 36.6 is one of the founding members of the Russian Association of Pharmacy Chains (RAPC). Pharmacy Chain 36.6 is a participating member of the international retailers' organizations – NRF and NACDS.

Pharmacy Chain 36.6 employs over 11.000 people.

THIS DOCUMENT IS NOT AN ADVERTISEMENT OF SECURITIES IN THE RUSSIAN FEDERATION. AND IS NOT AN OFFER TO SELL. OR AN INVITATION TO MAKE OFFERS TO PURCHASE. ANY SECURITIES IN THE RUSSIAN FEDERATION.

NOT FOR RELEASE. DIRECTLY OR INDIRECTLY. IN THE UNITED STATES OF AMERICA. AUSTRALIA. CANADA OR JAPAN.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. No public offering of the securities will be made in the United States.

This communication is being distributed only to and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments, i.e., investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth companies, unincorporated associations and other bodies to whom it may otherwise lawfully be communicated in accordance with Article 49 of the Order (all such persons together being referred to as "relevant persons"). The securities are available only to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be available only to or will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.